Page last updated: 2024-09-02

ecteinascidin 743 and Pancreatic Neoplasms

ecteinascidin 743 has been researched along with Pancreatic Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jusko, WJ; Koch, G; Miao, X; Straubinger, RM1
Allavena, P; Belli, C; Cangi, MG; Cappio, S; Ceraulo, D; D'Incalci, M; Doglioni, C; Dugnani, E; Garassini, G; Maggiora, P; Piemonti, L; Porcu, L; Reni, M; Zucchetti, M1

Trials

1 trial(s) available for ecteinascidin 743 and Pancreatic Neoplasms

ArticleYear
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Deoxycytidine; Dioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome

2016

Other Studies

1 other study(ies) available for ecteinascidin 743 and Pancreatic Neoplasms

ArticleYear
Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dioxoles; Drug Synergism; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Tetrahydroisoquinolines; Trabectedin

2016